ARTV(ARTV)
ARTV
ANALYST COVERAGE4 analysts
BUY
▲ +368.8%upside to target
L $35.00
Med $37.50consensus
H $40.00Key MetricsTTM
Market Cap$196.99M
Revenue TTM$0.00
Net Income TTM-$87.07M
Free Cash Flow-$80.18M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-73.2%
Return on Assets-82.2%
Debt / Equity0.12
Current Ratio8.16
EPS TTM$-3.53
PRICE
Prev Close
7.84
Open
7.83
Day Range7.73 – 8.34
7.73
8.34
52W Range1.47 – 14.53
1.47
14.53
50% of range
VOLUME & SIZE
Avg Volume
382.0K
FUNDAMENTALS
P/E Ratio
-2.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
55
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 120 days
Sep 18
ARTV News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Fred AslanPresident, Chief Executive Officer & Director
Jennifer Kinsbruner BushChief Operating Officer
David MoriartySenior Vice President of Clinical Operations
Andrew CronauerVP, General Counsel & Corporate Secretary
Benjamin DeweesSenior Vice President of Regulatory Affairs
Christopher HoranChief Technical Operations Officer
Feng XuSenior Vice President of Biometrics
Thad HustonCFO and Principal Financial & Accounting Officer
Heather RaymonSenior Vice President of Research & Early Development
Nicholas VeomettVice President of Corporate Development
Peter FlynnCo-Founder & Strategic Advisor
Subhashis BanerjeeChief Medical Officer